The application of ICP MS in clinical pharmacological oncology research
Ezine
- Published: Mar 3, 2008
- Channels: Atomic
The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research
Mass Spectrometry Reviews 2008, 27, 67-100
Elke E.M. Brouwers, Matthijs Tibben, H. Rosing, Jan H.M. Schellens, Jos H. Beijnen
Abstract: Metal-based anticancer agents are frequently used in the treatment of a wide variety of cancer types. The monitoring of these anticancer agents in biological samples is important to understand their pharmacokinetics, pharmacodynamics, and metabolism. In addition, determination of metals originating from anticancer agents is relevant to assess occupational exposure of health care personnel working with these drugs. The high sensitivity of inductively coupled plasma mass spectrometry (ICP-MS) has resulted in an increased popularity of this technique for the analysis of metal-based anticancer drugs. In addition to the quantitative analysis of the metal of interest in a sample, ICP-MS can be used as an ultrasensitive metal selective detector in combination with speciation techniques such as liquid chromatography. In the current review we provide a systematic survey of publications describing the analysis of platinum- and ruthenium-containing anticancer agents using ICP-MS, focused on the determination of total metal concentrations and on the speciation of metal compounds in biological fluids, DNA- and protein-adducts, and environmental samples. We conclude that ICP-MS is a powerful tool for the quantitative analysis of metal-based anticancer agents from multiple sample sources.
-
This paper is free to view to spectroscopyNOW registered users until the end of May 2008. After this time it will be available via Wiley's Pay-Per-View service for US$25.
-
Click here to access the abstract of this paper. From here you can progress to read the full paper.
-
Click here for more details about Mass Spectrometry Reviews